A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age

• Main Authors: Brandon Essink (Author), James Peterson (Author), Kari Yacisin (Author), Himal Lal (Author), Sarah Mirza (Author), Xia Xu (Author), Ingrid L. Scully (Author), Daniel A. Scott (Author), William C. Gruber (Author), Kathrin U. Jansen (Author), Wendy Watson (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Pneumococcal disease can be serious and debilitating in older adults. Pneumococcal conjugate vaccines (PCVs), such as the 13-valent PCV (PCV13), reduce pneumococcal disease rates caused by vaccine serotypes. Development of PCVs offering additional coverage against serotypes not contained in PCV13 ca...